

Global Cystic Fibrosis

Patient Information:

Name:

| | If you have any | Version | 00 2025 |
|---------------------------|---|---------------------------------------|------------|
| | kip to question 7.] | 100 | |
| | patient been receiving medication samples of the requested medication? | Yes | No |
| | atient currently receiving the requested medication? kip to question 7.] | Yes | No |
| - | | \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ | |
| ∏ Contin | uation (If checked, go to 2) | | |
| | equest an INITIAL or CONTINUATION of therapy? (If checked, go to 7) | | |
| | | | T |
| on COMAR red | quirements, MDH transmittals and updates to treatment quid | delines. | |
| medications th | at are not listed within the criteria. The policies are subject t | o chang | e based |
| | macy prior authorization reviews can be subject to trial with | | |
| SECTION A: P | lease note that supporting clinical documentation is required | d for AL | L PA |
| Upon receipt of th | e completed form, prescription benefit coverage will be determined based of | on the pla | n's rules. |
| quantities can be pro | ovided. Please complete the following questions then fax this form to the toll-free | number list | ed below. |
| | ription benefit requires that we review certain requests for coverage with the partient that requires Prior Authorization before benefit coverage or co | | |
| | | | |
| Diagnosis and IC | D Code: | | |
| Administration: | | | |
| Rx Frequency: Rx Route of | | | |
| Rx Quantity: | | | |
| Rx Strength | | | |
| Rx Name: | | | |
| Requested Medi | cation | | |
| City, State, Zip: | | | |
| Address: | | | |
| Fax Number | | | |
| Phone Number: | | | |
| NPI: | | | |
| Name: | | | |
| Prescriber Infor | mation: | | |
| Date of Birth: | | | |
| City, State, Zip: | | | |
| Address: | | | |
| Member ID: | | | |

questions, call: 1-888-258-8250

| 4 | Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 7.] | Yes | No |
|----|---|-----|----|
| 5 | Has the patient been established on therapy for at least 3 months? [If no, skip to question 7.] | Yes | No |
| 6 | Has documentation been submitted to confirm that the patient has had a significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of clinical presentation of cystic fibrosis include but are not limited to meconium ileus, sino-pulmonary symptoms include persistent cough, wheezing, pulmonary function tests consistent with obstructive airway disease, excess sputum production, bronchiectasis, sinusitis, failure to thrive, pancreatic insufficiency.] [No further questions.] | Yes | No |
| 7 | What is the indication or diagnosis? ACTION REQUIRED: Submit supporting documentation. [] Cystic Fibrosis (If checked, go to 8) [] Other (If checked, no further questions) | | |
| 8 | Is the medication requested being prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis? [If no, no further questions.] | Yes | No |
| 9 | Will the patient be taking the requested medication in combination with another medication used to treat Cystic Fibrosis? [If no, no further questions.] | Yes | No |
| 10 | What medication is required? [] Lumacaftor / Ivacaftor (Orkambi) (If checked, go to 11) | | |
| | [] Tezacaftor / Ivacaftor (Symdeko) (If checked, go to 13) | | |
| | [] Ivacaftor (Kalydeco) (If checked, go to 16) | | |
| | [] Elexacaftor / Tezacaftor / Ivacaftor (Trikafta) (If checked, go to 19) | | |
| | [] Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek) (If checked, go to 21) | | |

If you have any questions, call: 1-888-258-8250

| | [] Other (If checked, no further questions) | | |
|----|---|-----|----|
| 11 | Is the patient greater than or equal to 1 years of age? [If no, no further questions.] | Yes | No |
| 12 | Does the patient have cystic fibrosis that is homozygous for the F508del (Phe508del) mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene (this means the patient has two copies of the F508del (Phe508del) mutation)? ACTION REQUIRED: Submit supporting documentation. [Note: Documentation required is FDA-approved CF mutation test result.] [No further questions.] | Yes | No |
| 13 | Is the patient greater than or equal to 6 years of age? [If no, no further questions.] | Yes | No |
| 14 | Does the patient have at least one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (See Appendix A)? Please specify mutation: [Internal CRU note: Please confirm the mutation is in the list provided in Appendix A.] | | |
| | [] Yes (No further questions) | | |
| | [] No (If checked, go to 15) | | |
| | [] Unknown (If checked, no further questions) | | |
| 15 | Does the patient have two copies of the F508del mutation? ACTION REQUIRED: Submit supporting documentation. [Note: Documentation required is FDA-approved CF mutation test result.] [No further questions.] | Yes | No |
| 16 | Is the patient homozygous for the phe508del (F508del) mutation in the cystic fibrosis transmembrane regulator (CFTR) gene? [If yes, no further questions.] | Yes | No |
| 17 | Does the patient have at least one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N, G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D, 2789+5G>A, 3272-26A>G, 3849+10kbC>T, 711+3A>G, E831X, OR R117H? ACTION REQUIRED: Submit supporting documentation. [Note: Documentation required is FDA-approved CF mutation test result.] | | |
| | [] Yes (If checked, go to 18) | | |
| | [] No (If checked, no further questions) | | |

If you have any questions, call: 1-888-258-8250

| | | | 1 |
|----|--|-----|----|
| | [] Unknown (If checked, no further questions) | | |
| 18 | Is the patient greater than or equal to 1 month of age? [No further questions.] | Yes | No |
| 19 | Is the patient greater than or equal to 2 years of age? [If no, no further questions.] | Yes | No |
| 20 | Does the patient have at least one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (See Appendix B)? ACTION REQUIRED: Submit supporting documentation. [Note: Documentation required is FDA-approved CF mutation test result.] Please specify mutation: [Internal CRU note: Please confirm the mutation is in the list provided in Appendix B.] | | |
| | [] Yes (If checked, no further questions) | | |
| | [] No (If checked, no further questions) | | |
| | [] Unknown (If checked, no further questions) | | |
| 21 | Is the patient greater than or equal to 6 years of age? [If no, no further questions.] | Yes | No |
| 22 | Does the patient have at least one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (See Appendix C)? ACTION REQUIRED: Submit supporting documentation. [Note: Documentation required is FDA-approved CF mutation test result.] Please specify mutation: [Internal CRU note: Please confirm the mutation is in the list provided in Appendix C.] | | |
| | [] Yes (If checked, no further questions) | | |
| | [] No (If checked, no further questions) | | |
| | [] Unknown (If checked, no further questions) | | |
| | | | |

APPENDIX A

List of CFTR gene (Symdeco):

E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, 711+3A → G, S945L, S977F, F1052V, E831X, K1060T, A1067T, R1070W, F1074L, D1152H, D1270N, 2789+5G → A, 3272-26A → G, 3849 + 10kbC → T, 546insCTA, A120T, A234D, A349V, A554E, A1006E, D192G, D443Y, D443Y;G57A;R668C, D614G, D836Y, D924N, D979V, I618T, I807M, I980K, I1027T, I1139V, I1269N, I1366N, L15P, L320V, R170H, R258G, R334L, R334Q, R347L, R347P, R352W, R553Q, R668C, R751L, V1293G, E60K,

If you have any questions, call: 1-888-258-8250

E92K, E116K, E403D, E558V, E822K, F191V, F311del, F311L, F508C, F508C;S1251N, F575Y, L346P, L967S, L997F, L1324P, L1335P, L1480P, M152V, M265R, M9521, R1066H, R1070Q, R1162L, R1283M, R1283S, S549N, S549R, S589N, S737F, S912L, F1016S, F1099L, G126D, G178E, G178R, G194R, G194V, G314E, G551D, G551S, G576A, G576A;R668C, M952T, P5L, P205S, Q98R, Q237E, Q237H, Q359R, Q1291R, R31L, S1251N, S1255P, T338I, T1036N, T1053I, V201M, V232D, V562I, V754M, V1153E, G622D, G970D, G1069R, G1244E, G1249R, G1349D, H939R, H1054D, H1375P, I148T, I175V, I336K, I601F, R74Q, R74W;D1270N, R74W;V201M, R74W;V201M;D1270N, R75Q, R117G, R117H, R117L, R117P, W1282R, Y109N, Y161S, Y1014C, Y1032C, R792G, R933G, S1159F, S1159P, or V1240G.

APPENDIX B

List of CFTR gene (Trikafta):

F508del, 3141del9, E822K, G1069R, L967S, R117L, S912L, 546insCTA, F191V, G1244E, L997F, R117P, S945L, A46D, F311del, G1249R, L1077P, R170H, S977F, A120T, F311L, G1349D, L1324P, R258G, S1159F, A234D, F508C, H139R, L1335P, R334L, S1159P, A349V, F508C; S1251N, H199Y, L1480P, R334Q, S1251N, A455E, H939R, M152V, R347H, S1255P, A554E, F575Y, H1054D, M265R, R347L, T338I, A1006E, F1016S, H1085P, M952I, R347P, T1036N, A1067T, F1052V, H1085R, M952T, R352Q, T1053I, D110E, F1074L, H1375P, M1101K, R352W, V201M, D110H, F1099L, I148T, P5L, R553Q, V232D, D192G, G27R, I175V, P67L, R668C, V456A, D443Y, G85E, I336K, P205S, R751L, V456F, D443Y; G576A; R668C, G126D, I502T, P574H, R792G, V562I, D579G, G178E, I601F, Q98R, R933G, V754M, D614G, G178R, I618T, Q237E, R1066H, V1153E, D836Y, G194R, I807M, Q237H, R1070Q, V1240G, D924N, G194V, I980K, Q359R, R1070W, V1293G, D979V, G314E, I1027T, Q1291R, R1162L, W361R, D1152H, G463V, I1139V, R31L, R1283M, W1098C, D1270N, G480C, I1269N, R74Q, R1283S, W1282R, E56K, G551D, I1366N, R74W, S13F, Y109N, E60K, G551S, K1060T, R74W;D1270N, S341P, Y161D, E92K, G576A, L15P, R74W; V201M, S364P, Y161S, E116K, G576A; R668C, L165S, R74W:V201M:D1270N, S492F, Y563N, E193K, G622D, L206W, R75Q, S549N, Y1014C, E403D, G628R, L320V, R117C, S549R, Y1032C, E474K, G970D, L346P, R117G, S589N, E588V, G1061R, L453S, R117H, S737F, 1507 151del9, 2183A→G, 2789+5G→A, 3272-26A→G, 3849+10kbC→T, A107G, A309D, A262P, 491R, D1445N, D565G, D993Y, E116Q, E292K, E403D, F1107L, F2001, F587I, G1047R, G1123R, G12474R, G27E, G424S, G480S, G551A, G970S, H620P, H260Q, H939R; H949L, I105N, I125T, I1331N, I148N, 1506L, I556V, K162E. K464E, L1011S, L137P, L333F, L333H, L441P, L619S, 1137V, M150K, N1088D, N1303K, N1303I, N186K, N187K, N418S, P140S, P499A, P705L, Q1313K, Q372H, Q493R, Q552P, R1048G, R117;G576A;R668C, R297Q, R31C, R334L, R516S, F555G, R709Q, R75L, S1045Y, S108F, S1118F, S1235R, T1086I, T1246I, T1299I, V392G, V603F, Y301C, 4005+2T→C, 2789+2insA, 3849+40A→G, 5T;TG13, 1341G→A, 296+28A→G, 3849+4A→G, 621+3A→G, 1898+3A→G, 304115T→G, 3850-3T→G, 711+3A→G, 2752-26A→G, 3600G→A, 5T;TG12, or E831X.

APPENDIX C

List of CFTR gene (Alyftrek):

F508del, A455E, G551D, L1077P, R352Q, S549N, V754M, D1152H, G85E, L206W, R75Q, S549R, W1098C, H1054D, M1101K, S1159F, S945L, W1282R, G1244E, I336K, R1066H, S1251N, V562I, Y563N, 1507_1515del9, E116Q, G424S, I556V, P140S, R334L, T1053I, 2183A→G, E193K, G463V, I601F, P205S, R334Q, T1086I, 3141del9, E292K, G480C, I618T, P499A, R347H, T1246I, 3195del6, E403D, G480S, I807M, P5L, R347L, T1299I, 3199del6, E474K, G551A, I980K, P574H, R347P, T338I, 546insCTA, E56K, G551S, K1060T, P67L, R352W, T351I, A1006E, E588V, G576A, K162E, P750L, R516G, T604I, A1067P, E60K, G576A;R668C, K464E, P99L, R516S, V1153E, A1067T, E822K, G622D, L1011S, Q1100P, R553Q, V1240G, A107G, E92K, G628R, L102R, Q1291R, R555G, V1293G, A120T, F1016S, G91R, L1065P, Q1313K, R560S, V201M, A234D, F1052V, G970D, L1324P, Q237E, R560T, V232D, A309D, F1074L, G970S, L1335P, Q237H, R668C, V392G, A349V, F1099L, H1085P, L137P, Q359R, R709Q, V456A, A46D, F1107L, H1085R, L1480P, Q372H, R74Q, V456F, A554E, F191V, H1375P, L15P, Q452P, R74W, V520F, A559T, F200I, H139R, L165S, Q493R, R74W;D1270N, V603F, A559V, F311del, H199R, L320V, Q552P, R74W;V201M, W361R, A561E, F311L, H199Y, L333F, Q98R, R74W;V201M;D,

If you have any questions, call: 1-888-258-8250

Version 09.2025



1270N, Y1014C, A613T, F508C, H609R, L333H, R1048G, R75L, Y1032C, A62P, F508C;S1251N, H620P, L346P, R1066C, R751L, Y109N, A72D, F575Y, H620Q, L441P, R1066L, R792G, Y161D, C491R, F587I, H939R, L453S, R1066M, R933G, Y161S, D110E, G1047R, H939R;H949L, L619S, R1070Q, S1045Y, Y301C, D110H, G1061R, I1027T, L967S, R1070W, S108F, Y569C, D1270N, G1069R, I105N, L997F, R1162L, S1118F, Y913C, D1445N, G1123R, I1139V, M1101R, R117C, S1159P, D192G, G1247R, I1234Vdel6aa, M1137V, R117C;G576A;R668C, S1235R, D443Y, G1249R, I125T, M150K, R117G, S1255P, D443Y;G576A;R668C, G126D, I1269N, M152V, R117H, S13F, D513G, G1349D, I331N, M265R, R117L, S341P, D565G, G149R, I1366N, M952I, R117P, S364P, D579G, G178E, I1398S, M952T, R1283M, S492F, D614G, G178R, I148N, N1088D, R1283S, S549I, D836Y, G194R, I148T, N1303I, R170H, S589N, D924N, G194V, I175V, N1303K, R258G, S737F, D979V, G27E, I502T, N186K, R297Q, S912L, D993Y, G27R, I506L, N187K, R31C, S977F, E116K, G314E, I506T, N418S, R31L, T1036N, 1341G \rightarrow A, 2789+2insA, 3041-15T \rightarrow G, 3849+10kbC \rightarrow T, 3850-3T \rightarrow G, 5T;TG13, 711+3A \rightarrow G, 1898+3A \rightarrow G, 2789+5G \rightarrow A, 3272-26A \rightarrow G, 3849+4A \rightarrow G, 4005+2T \rightarrow C, 621+3A \rightarrow G, E831X 2752-26A \rightarrow G, 296+28A \rightarrow G, 3600G \rightarrow A, 3849+40A \rightarrow G, 5T;TG12.

| SECTION B: Physician Signature | | |
|--------------------------------|--|--|
| | | |

Please document the diagnoses, symptoms, and/or any other information important to this review:

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

PHYSICIAN SIGNATURE

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 09.2025

DATE